Creatine is a molecule that supports energy metabolism in cells. It is carried across the plasma membrane by the creatine transporter. There has been recent interest in creatine for its neuroprotective effects in neurodegenerative diseases and its potential as a therapeutic agent. This study represents the first systematic investigation of the distribution of the creatine transporter in the human brain. We have used immunohistochemical techniques to map out its location and the intensity of staining. The transporter was found to be strongly expressed, especially in the large projection neurons of the brain and spinal cord. These include the pyramidal neurons in the cerebral cortex, Purkinje cells in the cerebellar cortex, and motor neurons of the somatic motor and visceromotor cranial nerve nuclei and the ventral horn of the spinal cord. Many other neurons in the brain also had some degree of creatine transporter immunoreactivity. By contrast, the medium spiny neurons of the striatum and the catecholaminergic neurons of the substantia nigra and locus coeruleus, which are implicated in neurodegenerative diseases, showed a very low to almost absent level of immunoreactivity for the transporter. We propose that the distribution may reflect the energy consumption by different cell types and that the extent of creatine transporter expression is proportional to the cell's energy requirements. Furthermore, the distribution indicates that supplemented creatine would be widely taken up by brain cells, although possibly less by those cells that degenerate in Huntington's and Parkinson's diseases.
Pubmed ID: 25159005 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets CD31
View all literature mentionsThis monoclonal targets Calbindin D-28k
View all literature mentionsThis monoclonal targets VGAT (cytoplasmic domain)
View all literature mentionsThis unknown targets
View all literature mentionsThis monoclonal targets Neurofilament H
View all literature mentionsThis polyclonal targets Human Olig2
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis unknown targets Calretinin
View all literature mentionsThis monoclonal targets parvalbumin
View all literature mentionsThis polyclonal targets VGluT2
View all literature mentionsThis monoclonal targets Neurofilament H
View all literature mentionsSoftware for image processing, analysis, and editing. The software includes features such as touch capabilities, a customizable toolbar, 2D and 3D image merging, and Cloud access and options.
View all literature mentionsThis monoclonal targets Neurofilament H
View all literature mentionsThis monoclonal targets Calbindin D-28k
View all literature mentionsThis polyclonal targets Human Olig2
View all literature mentionsThis monoclonal targets Calbindin D-28k
View all literature mentionsThis unknown targets Calretinin
View all literature mentionsThis monoclonal targets parvalbumin
View all literature mentionsThis monoclonal targets VGAT (cytoplasmic domain)
View all literature mentionsThis monoclonal targets CD31
View all literature mentionsThis polyclonal targets Human Olig2
View all literature mentionsThis monoclonal targets GFAP
View all literature mentions